FISH FGFR1 8p12 Gene Rearrangement Test
Comprehensive Genetic Analysis for Leukemia Diagnosis
The FISH FGFR1 8p12 Gene Rearrangement Test represents a cutting-edge molecular diagnostic approach that plays a pivotal role in modern hematological cancer management. This specialized cytogenetic test utilizes advanced fluorescence in situ hybridization (FISH) technology to detect specific genetic abnormalities involving the FGFR1 gene on chromosome 8p12, providing crucial information for accurate leukemia diagnosis and personalized treatment planning.
What Does This Test Measure?
The FISH FGFR1 8p12 Gene Rearrangement Test specifically detects:
- FGFR1 gene rearrangements and translocations on chromosome 8p12
- Genetic abnormalities associated with 8p11 myeloproliferative syndrome
- Specific fusion genes resulting from FGFR1 rearrangements
- Chromosomal abnormalities that drive hematological malignancies
Who Should Consider This Test?
This advanced genetic test is recommended for individuals presenting with:
- Suspected 8p11 myeloproliferative syndrome
- Unexplained eosinophilia or basophilia
- Myeloproliferative neoplasms with atypical features
- Lymphoblastic lymphoma with eosinophilia
- Patients with stem cell leukemia/lymphoma syndrome
- Individuals with persistent blood count abnormalities
- Patients requiring precise genetic characterization of hematological malignancies
Clinical Benefits of FGFR1 Testing
Undergoing the FISH FGFR1 8p12 Gene Rearrangement Test provides numerous clinical advantages:
- Accurate Diagnosis: Precise identification of FGFR1-related hematological disorders
- Treatment Guidance: Information crucial for selecting appropriate targeted therapies
- Prognostic Assessment: Better understanding of disease progression and outcomes
- Family Risk Evaluation: Assessment of potential hereditary factors
- Monitoring Tool: Baseline for tracking treatment response and disease progression
Understanding Your Test Results
Your FISH FGFR1 8p12 Gene Rearrangement Test results will be carefully interpreted by our expert cytogeneticists:
- Positive Result: Indicates presence of FGFR1 gene rearrangement, confirming specific hematological malignancies
- Negative Result: Suggests absence of detectable FGFR1 rearrangements
- Consultation: Results are reviewed with your oncologist or hematologist for comprehensive clinical correlation
- Follow-up: Additional testing may be recommended based on clinical findings
Test Pricing Information
| Price Type | Amount (USD) |
|---|---|
| Discount Price | $150 |
| Regular Price | $212 |
Sample Requirements and Processing
For accurate testing, we require:
- Sample Type: 5 mL (3 mL minimum) whole blood OR 4 mL (2 mL minimum) Bone Marrow
- Collection Tubes: 2 Green Top (Sodium Heparin) tubes
- Shipping: Maintain at 18-22°C during transport
- Important: DO NOT FREEZE samples
- Required Documentation: Duly filled Chromosome & FISH analysis Requisition Form (Form 17)
Turnaround Time and Reporting
Our laboratory maintains efficient processing standards:
- Sample Acceptance: Daily by 4 pm
- Report Delivery: 4 Working days from sample receipt
- Expert Review: All results reviewed by certified cytogeneticists
- Secure Delivery: Results provided through secure patient portal or direct to healthcare provider
Nationwide Testing Availability
GGC DNA provides comprehensive genetic testing services across the United States with branches in all major cities including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network ensures accessible, high-quality genetic testing for patients nationwide.
Book Your Test Today
Take the first step toward precise genetic diagnosis and personalized treatment planning. Our team of genetic specialists and certified laboratory professionals are ready to assist you with comprehensive genetic testing services.
Call or WhatsApp: +1(267) 388-9828
Schedule your FISH FGFR1 8p12 Gene Rearrangement Test today and benefit from our advanced cytogenetic testing capabilities. Early and accurate genetic diagnosis can significantly impact treatment outcomes and disease management strategies.

